文献速递垂体与肾上腺疾病

Addison病与先天性肾上腺增生患者感染风险增加

Increased Infection Risk in Addison's Disease and Congenital Adrenal Hyperplasia.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

基于英国1995至2018年数据的回顾性队列研究,纳入1580例Addison病和602例先天性肾上腺增生(CAH)成人患者。暴露于糖皮质激素的AD和CAH患者下呼吸道、泌尿道及胃肠道感染风险显著升高,抗菌药物处方量亦增加;未用糖皮质激素的CAH患者无此风险。

要点

  • 接受糖皮质激素治疗的AD和CAH患者感染风险及抗菌药物使用显著增加。
  • 未接受糖皮质激素治疗的CAH患者感染风险未见显著升高。
  • 感染风险增加至少部分与糖皮质激素治疗相关。

核心结论

  • 在初级保健环境中,原发性肾上腺皮质功能不全(PAI)患者感染风险和抗菌药物使用增加,至少部分与糖皮质激素治疗相关。

研究设计与样本

  • 回顾性队列研究,使用英国1995至2018年收集的数据,比较成人PAI患者与未暴露对照的感染发生率。
  • 诊断PAI的Addison病(AD)患者1580例(平均年龄51.7岁),先天性肾上腺增生(CAH)患者602例(平均年龄35.4岁)。

主要发现

  • 暴露于糖皮质激素的AD和CAH患者下呼吸道感染(LRTI)风险显著增加:AD调整发病率比2.11(95%CI 1.64-2.69),CAH 3.23(95%CI 1.21-8.61)。
  • 泌尿道感染(UTI)风险显著增加:AD 1.51(95%CI 1.29-1.77),CAH 2.20(95%CI 1.43-3.34)。
  • 胃肠道感染(GII)风险显著增加:AD 3.80(95%CI 2.99-4.84),CAH 1.93(95%CI 1.06-3.52)。
  • 抗菌药物处方增加:AD 1.73(95%CI 1.69-1.77),CAH 1.77(95%CI 1.66-1.89);抗真菌药物处方增加:AD 1.89(95%CI 1.74-2.05),CAH 1.91(95%CI 1.50-2.43)。
  • 未接受糖皮质激素治疗的CAH患者感染风险未见显著增加。

关键数值与推荐

  • 所有AD患者和42%的CAH患者被处方糖皮质激素,AD最常用氢化可的松(82%),CAH最常用泼尼松龙(50%)。

临床怎么用

  • 对接受糖皮质激素治疗的AD和CAH患者应警惕感染风险,并关注抗菌药物使用情况。
  • 未来需研究更符合生理的糖皮质激素替代方案是否可降低感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Mortality and infection-related hospital admissions are increased in patients with primary adrenal insufficiency (PAI). However, the risk of primary care-managed infections in patients with PAI is unknown. OBJECTIVE: To estimate infection risk in PAI due to Addison's disease (AD) and congenital adrenal hyperplasia (CAH) in a primary care setting. DESIGN: Retrospective cohort study using UK data collected from 1995 to 2018. MAIN OUTCOME MEASURES: Incidence of lower respiratory tract infections (LRTIs), urinary tract infections (UTIs), gastrointestinal infections (GIIs), and prescription counts of antimicrobials in adult PAI patients compared to unexposed controls. RESULTS: A diagnosis of PAI was established in 1580 AD patients (mean age 51.7 years) and 602 CAH patients (mean age 35.4 years). All AD patients and 42% of CAH patients were prescribed glucocorticoids, most frequently hydrocortisone in AD (82%) and prednisolone in CAH (50%). AD and CAH patients exposed to glucocorticoids, but not CAH patients without glucocorticoid treatment, had a significantly increased risk of LRTIs (adjusted incidence rate ratio AD 2.11 [95% confidence interval (CI) 1.64-2.69], CAH 3.23 [95% CI 1.21-8.61]), UTIs (AD 1.51 [95% CI 1.29-1.77], CAH 2.20 [95% CI 1.43-3.34]), and GIIs (AD 3.80 [95% CI 2.99-4.84], CAH 1.93 [95% CI 1.06-3.52]). This was mirrored by increased prescription of antibiotics (AD 1.73 [95% CI 1.69-1.77], CAH 1.77 [95% CI 1.66-1.89]) and antifungals (AD 1.89 [95% CI 1.74-2.05], CAH 1.91 [95% CI 1.50-2.43]). CONCLUSIONS: There is an increased risk of infections and antimicrobial use in PAI in the primary care setting at least partially linked to glucocorticoid treatment. Future studies will need to address whether more physiological glucocorticoid replacement modes could reduce this risk.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tresoldi AS, Sumilo D, Perrins M, et al. Increased Infection Risk in Addison's Disease and Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2020. PMID: 31532828. doi:10.1210/clinem/dgz006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。